SCPH / scPharmaceuticals: Oversold Territory, Drug Launch Still Looks Robust

Positive FDA feedback for Furoscix's label expansion into chronic kidney disease signals the potential for significant market growth. Introduction of more_horizontal

Today, we take our first look at scPharmaceuticals Inc., which has received positive analyst commentary but has a large short position in the stock. T more_horizontal

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants PJ Kelleher - Investor Relation more_horizontal

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares more_horizontal

The heavy selling pressure might have exhausted for scPharmaceuticals, Inc. (SCPH) as it is technically in oversold territory now. In addition to this more_horizontal

scPharmaceuticals' Furoscix dose-filling rates increased by 55% month over month in May. Despite the lower figures than market expectations, SCPH stoc more_horizontal

SCPH's Furoscix, despite just launching, defied street consensus with an impressive $2.1M revenue in 1Q23, indicating a promising ramp trajectory. Wit more_horizontal

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares more_horizontal